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Abstract 
Aims/Introduction: There is uncertainty about the direct medical costs of type 2 diabetes 
mellitus (T2DM) patients with cancers. 
 
Materials and Methods: A population-based retrospective cohort of 99915 T2DM patients 
from Hong Kong Hospital Authority between 2006 and 2017 was assembled. 16869 patients 
who had initial cancer diagnosis after T2DM were matched with 83046 patients without cancer 
(controls) using a matching ratio up to one-to-five propensity score-matching method. Patients 
were divided into four categories according to life expectancy. Healthcare service utilization 
and direct medical costs during the index year, subsequent years, and mortality year were 
compared between patients with and without cancer in each category.  
 
Results: Medical costs of cancer patients in index year ranged from US$27533 for patients 
died <1 year to US$11303 for those survived >3 years. Cancer patients had significantly greater 
expenditures than controls in index year (all P<0.001) and subsequent years (US$4569 vs. 
US$4155, P<0.001). Cancer patients also had greater costs in the death year, and the difference 
was significant for patients who survived >3 years after index year (US$32558 vs. US$28260). 
For patients in both groups, patients who survived >3 years had significantly lower costs than 
those died <1 year. Costs incurred in mortality year were greater than those in index year and 
subsequent years. Hospitalization accounted for >90% of the medical costs for both groups in 
mortality year.  
 
Conclusions: T2DM patients with cancers incurred greater medical costs in the diagnosis, 
ensuing, and mortality years than T2DM patients without cancers. 
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Introduction 
 
Cancer causes a tremendous disease burden worldwide1. As the leading cause of death globally, 
cancer accounts for 18.1 million new cases and 9.6 million deaths in 20182. The incidence of 
cancer has increased over the years, and its upward trend is partly due to the rising prevalence 
of risk factors such as diabetes, obesity and other lifestyle factors 1. An increasing number of 
studies confirm that type 2 diabetes mellitus (T2DM) is associated with an increased risk of 
cancer and cancer mortality 3-8. Indeed, patients with T2DM have higher incidence across all 
cancer types with Risk ratio of 1.23 for Asian patients and 1.15 for non-Asian patients 9. For 
hepatocellular carcinoma, particular, the increased risk among patients with T2DM reaches to 
131% 10. In view of the strong link between diabetes and the incidence of cancer, a joint 
consensus statement convened by the American Diabetes Association (ADA) and the 
American Cancer Society stated that T2DM patients are more likely to develop cancers in liver, 
pancreas, endometrium, colon and rectum, breast and bladder, although they are less likely to 
develop prostate cancer11.  
 
The economic burden of cancers is tremendously heavy from either a macroscopic or an 
individual perspective12-14. The estimated direct medical costs and indirect costs resulting from 
a loss of productivity among cancer patients has reached US$2 trillion globally15. At an 
individual level, up to $81655 was accrued in the post-diagnosis period for each cancer patient 
who died within 1 year16. Of note, oncology patients who died within 1 year after diagnosis 
tended to have higher medical costs than those who survived beyond 1 year in the post-
diagnosis periods16. This is probably because the cost of treating cancer increases with the 
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advancement of the disease, as extra treatments, intensive care and expensive drugs are given 
during the end-of-life care17,18. 
 
In recent years, the increasing use of computer simulation models of diabetes progression in 
clinical decision-making processes has addressed clinical questions with long-term simulated 
results19. While diabetes-related complications, including cardiovascular diseases, retinopathy, 
nephropathy and amputation, have been widely included in existing economic evaluations of 
interventions for T2DM, none of them considered cancers as one of modelled complications 
20, even though the guidelines for economic models of diabetes advocate a compression of 
multiple diabetes complications21. Since T2DM is associated with an increased risk of cancer 
and the burden of cancer is heavy, diabetes economic models could be further refined by 
introducing cancers. However, no known studies measured the direct medical costs of T2DM 
patients co-existing with cancer, and thus it remains a great challenge to incorporate cancer 
into the model.  
 
This population-based cohort study aimed to 1) examine the direct medical costs of T2DM 
patients with cancers in the year of diagnosis, ensuing years and year of death by their life 
expectancies; 2) compare the costs of T2DM patients with and without cancers; and 3) assess 
the impact of patients’ baseline covariates on direct medical costs.  
 
Materials and Methods 
 
Study design and population 
A retrospective propensity score-matched cohort study was conducted. Patients who used the 
Hong Kong Hospital Authority (HA) healthcare services between January 2006 and December 
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2017 were identified from the HA Clinical Management System (CMS). Disease diagnosis was 
identified according to the International Classification of Diseases, Ninth Revision, Clinical 
Modification (ICD-9-CM) and International Classification of Primary Care, Second Edition 
(ICPC-2) (Supplemental Table 1). A one-year screening period was adopted to exclude 
patients whose cancer diagnosis was made in or before the year 2006. Patients who had cancer 
diagnosis on or after the onset date of T2DM were assigned to the cancer group. The index 
date was defined as the date of the first occurrence of a cancer event during the study period. 
To fully use the large pool of non-cancer patients, a group of T2DM patients without a recorded 
cancer diagnosis during the observation period was matched in a ratio up to one-to-five ratio 
using caliper propensity score matching.  
 
Outcomes  
Primary outcomes were the direct medical costs of patients in the cancer and control group 
incurred in the index year, ensuing years, and the last year of life. For patients in the cancer 
group, direct medical costs were further measured by tumour sites. 
 
Secondary outcomes included the pattern of use of healthcare services in T2DM patients with 
and without cancer and the impacts of patients’ baseline characteristics on medical costs. 
 
Estimation of direct medical costs 
The dates and types of healthcare service use by patients in both groups during the observation 
period were retrieved. Cost items included General Outpatient Clinic (GOPC) visits, Specialist 
Outpatient Clinic (SOPC) visits, Accident & Emergency (A&E) visits, applied health 
professional visits, and length of stay in a general ward, in an Intensive Care Unit (ICU), in a 
Coronary Care Unit (CCU), and in a High Dependency Unit (HDU). The unit cost of each type 
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of healthcare services was extracted from the public charges to non-eligible persons listed in 
the 2017 Government Gazette and HA Ordinance (Chapter 113) (Supplemental Table 2)22. 
The pegged exchange rage of US$1=HK$7.80 was used to convert Hong Kong dollars to US 
dollars23. The annual direct medical costs of each patient were calculated by summing up the 
unit cost of each healthcare service multiplied by the frequency of use of the respective service. 
 
Patients in both groups were divided into four categories by their life expectancies after the 
index year, including those who 1) died within 1 year after the index date (Category 1); 2) 
survived over 1 year, but died within 2 years after the index date (Category 2); 3) survived over 
2 years, but died within 3 years after the index date (Category 3); and 4) survived over 3 years 
after the index date (Category 4). Costs in the index year were the costs incurred from the index 
date to 1 year after the index date, while the costs incurred in the mortality year were the costs 
incurred from 1 year before the mortality date to the death date. Of note, costs in the index year 
of patients in Category 1 were also the costs of the mortality year. To avoid duplicate 
calculations, costs incurred beyond the index year were regarded as the costs in the mortality 
year for patients in Category 2. Only patients in Category 4 had the costs in the ensuing years, 
which were the mean value of the costs incurred between 1 year after the index date and 1 year 
before the death date (for patients who died during the observation period) or the mean value 
of the costs incurred between 1 year after the index date and the last observation date (for 
patients who survived during the whole observation period). 
 
Baseline covariates  
The baseline covariates included gender (male, female), age (≤75, >75), Charlson Comorbidity 
Index (CCI) (≤3, 4-6, ≥7), duration of T2DM (≤5, >5 years), presence of comorbidities 
(including mental health problems, hyperlipidaemia, obstructive sleep apnoea [OSA], 
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gallbladder disease, musculoskeletal and chronic orthopaedic disorders, end-stage renal 
diseases [ESRD] and hypertension), and the use of insulin, oral anti-diabetic drugs, anti-
hypertensive drugs and lipid-lowering agents.  
 
Statistical Analysis 
Propensity Score Matching Method 
Multiple imputation by chained equations was used to address the absence of baseline data 24. 
HbA1c, systolic blood pressure, diastolic blood pressure, low-density lipoprotein cholesterol, 
total cholesterol, high-density lipoprotein cholesterol, triglyceride and fasting glucose were 
imputed by demographics (gender and age), body mass index, history of comorbidities 
(including mental health problems, hyperlipidaemia, OSA, gallbladder diseases, 
musculoskeletal and chronic orthopaedic disorders, and hypertension), and the use of 
medications (including insulin, oral antidiabetic drugs, antihypertensive drugs, and lipid-
lowering drugs). Missing percentages for HbA1c, systolic blood pressure, diastolic blood 
pressure, LDL-C, total cholesterol, HDL-C, triglyceride and fasting glucose were 3.97%, 
9.34%, 9.42%, 10.12%, 9.53%, 9.97%, 9.97% and 10.62%, respectively. Model parameters 
estimated from multiple imputed data were used to obtain multiple-imputation linear 
predictions by applying Rubin’s combination rules observation wise to the completed-data 
predictions25. The obtained predictions were then used in propensity score matching. Each 
patient’s propensity score was computed by multivariable logistic regression adjusting for 
baseline clinical parameters and covariates. Command ‘calipmatch’ in STATA with a caliper 
width of 0.05 was used to match cancer patients with controls on a one-to-five basis. 
 
The baseline characteristics of patients before and after matching were presented by frequency 
with percentages for categorical variables and means with standard deviation (SD) for 
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continuous variables in a table. Independent t-tests or chi-squire tests were used to determine 
if there were significant differences between cancer and non-cancer patients. Standard mean 
difference (SMD), a statistic less sensitive to sample size, was calculated for each characteristic. 
An SMD of <0.2 indicated that the baseline characteristics between cancer patients and controls 
were well balanced26. 
 
Generalised linear models 
Generalised linear models (GLMs) with log link and gamma distribution were used to explore 
the effects of patient covariates on direct medical costs. GLMs were constructed separately for 
each Category. Multipliers (exponential value of coefficients), corresponding 95% confidence 
intervals (CIs) and p-values for each covariate were reported.  
 
All statistical analysis was done with Stata 13.1 (StataCorp LP, College Station, Texas). All 
significance tests were two-tailed and the p-value <0.05 was statistically significant. 
 
Results 
 
Patient characteristics 
A total of 16869 and 83046 eligible cancer and control patients respectively were included in 
this analysis. (Supplemental Figure 1)  
 
Table 1 summarises the baseline characteristics of patients before and after the propensity-
score matching. The baseline characteristics of the cancer and control patients were well 
balanced (Supplemental Figure 2). There were 4811, 1377, 725 and 9956 cancer patients with 
a median follow-up duration of 3, 16, 29, and 41 months in Categories 1 to 4, respectively. 
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There were 2795, 2752, 2575, and 74924 control patients in Categories 1 to 4, respectively. 
The median follow-up duration of the controls was 5, 17, 29, and 47 months in Categories 1 to 
4, respectively. 
 
Utilization of healthcare services 
Table 2 summarises the use of healthcare services by patients in the cancer and control groups. 
Notably, the SOPC was the most frequently used healthcare services by all categories, apart 
from cancer patients’ use of inpatient services. The frequency of SOPC visits by cancer patients 
ranged from 5.28 to 15.76 times, while those of control patients was less than five times across 
the four categories. Cancer patients had more SOPC visits than controls within the same 
category. A&E and allied health professional admissions tended to be more frequent for cancer 
patients than control patients during the observation period. However, the frequency of visits 
to GOPCs by patients in the cancer and control groups were similar. 
 
Compared with controls in the same category, cancer patients spent approximately 10 
additional nights in general wards in the index year and three extra nights in general wards in 
the mortality year. However, both cancer and control patients in Categories 1-4 spent less than 
one night in ICU, CCU and HDU wards. 
 
Direct medical costs 
Figure 1 shows the mean direct medical costs of cancer and control patients in the index year, 
subsequent years and the mortality year. For patients in Category 1, the direct medical costs of 
cancer and control patients in the index year were US$27533 and US$21043, respectively 
(P<0.001). Hospitalization accounted for the largest proportion (>95%) of the direct medical 
costs for both groups. Cancer patients in Category 2 had higher medical costs than control 
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patients in both the index year (US$26988 vs. US$15542, P<0.001) and the mortality year 
($21790 vs. US$21343, P=0.594). Similarly, cancer patients in Category 3 had higher costs in 
the index year (US$18695 vs. US$9121, P<0.001) and the mortality year (US$30433 vs. 
US$29608, P=0.534), but the differences were not significant in the mortality year. For patients 
in Category 4, the medical costs of cancer patients were significantly higher than those of 
controls in the index year, subsequent years and the mortality year (all P<0.001). Compared 
with patients in other categories, patients in Category 4 incurred less expenditure in 
hospitalization in the index year. However, the costs of hospitalization, again, were in excess 
of 90% of the total medical costs in the mortality year for patients in both the cancer and control 
groups. Of note, patients with longer remaining life expectancies had lower medical costs in 
the index year. 
 
We further grouped the costs incurred in the index year and in the mortality year for patients 
in all four Categories, and compared their annualised mean costs across patients in the four 
Categories and between the two groups (Supplemental Figure 3). Cancer patients in all four 
Categories had significantly greater medical costs in the index year than in the mortality year 
(all P<0.001). In group comparisons, patients in Category 2, more of whom had aggressive 
cancers with high mortality rates (e.g. cancers in digestive organs and unspecified sites), had 
the highest medical costs; while patients in Category 4, among who there are less patients with 
aggressive cancers, had the lowest.  
  
The mean direct medical cost of cancer patients in the index year, subsequent years and 
mortality year are displayed by tumour sites in Table 3. The direct medical costs of patients in 
Category 1 ranged from US$24478.15 (SD=US$1023.28) in patients with cancers in other and 
unspecified sites to US$42066.32 (SD=US$8380.46) for patients with cancers of the lip, oral 
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cavity and pharynx. The patients in Category 2 with cancers in lymphatic and hematopoietic 
tissue had the highest costs in the index year (US$33762.93, SD=US$8612.39), and patients 
with cancers of the lip, oral cavity and pharynx had the highest costs in the mortality year 
(US$28072.39, SD=US$8233.23). Patients in Category 3 with lymphatic cancers and leukemia 
had the highest direct medical costs in both the index year (US$28706.56, SD=US$12983.92) 
and the mortality year (US$39598.94, SD=US$12 817.13). Finally, the medical costs of 
patients in Category 4 in the index year ranged from US$7133.32 (SD=US$472.55) to 
US$18429.11 (SD=US$2839.51); the direct medical costs in the subsequent years were around 
US$4600 per year for all cancer patients.  
 
Effects of patients’ covariates on annual direct medical costs 
Table 4 shows the influence of baseline patients’ covariates on the annual direct medical costs 
by category. The base-case annual mean medical costs for a T2DM female patient belonging 
to Category 1, aged ≤75 years, who did not have cancer or other diabetic complications were 
US$14366.22. Oncology patients incurred significantly greater medical costs than non-cancer 
patients, with a multiplier of 1.470 (P<0.001). Medical costs were greater for patients aged 75 
or under (P<0.001). Compared with patients with a CCI ≤3, patients with a higher CCI had 
greater medical costs. The presence of gallbladder disease, ESRD and hypertension 
significantly increased the medical costs for patients in Category 1, while the presence of other 
diabetic complications did not have and a significant influence on annual costs. Of note, 
patients using insulin had significantly higher medical costs, while those taking oral anti-
diabetic drugs, anti-hypertensives or lipid-lowering agents had significantly lower costs.  
 
The occurrence of cancer in patients of all other categories significantly increased the medical 
costs in the index year, subsequent years and the mortality years. Generally, a higher CCI, the 
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presence of diabetic complications and the use of insulin increased annual medical costs, while 
the use of oral anti-diabetic drugs, anti-hypertensives, or lipid-lowering agents decreased them.  
 
Discussion 
 
This large-scale population-based cohort study estimated the direct medical costs and described 
the patterns of uptake of healthcare services by patients with both cancer and T2DM. This 
study also estimated the influence of patients’ characteristics on direct medical costs and 
provided cost information of patients with specific tumours. The use of a propensity-score 
matching method enabled the cost comparison between cancer and control patients by using 
real-world data. Results of GLMs facilitated easy estimation of medical costs incurred by 
patients with different baseline characteristics.  
 
This study filled the research gap and separately reported the medical costs incurred by T2DM 
patients with and without cancers by years. Several previous health economic evaluations had 
focused on the medical costs of either cancers or T2DM12,13,27-30, but none had quantified the 
impacts of cancer on the direct medical costs and healthcare utilization of T2DM patients, 
given the intrinsic connections between the two diseases. In addition, few of them reported the 
medical costs separately by the diagnosis year, subsequent years and mortality year28,31,32.  
 
This study also showed that greater medical expenditures were incurred in the mortality year. 
Of special note was that the overall medical and inpatient costs of oncology patients with a 
remaining life expectancy greater than 3 years had a U-shaped curve, i.e. higher costs were 
incurred in the year of diagnosis and mortality, while costs were lower in the years in between. 
In comparison, the medical costs of T2DM patients without cancer showed an increasing trend 
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over the years. Similar findings were supported by previous studies, which found that costs of 
cancer patients had a typical U-shaped curve while medical costs of T2DM patients increased 
overtime 28,31. The increased medical costs in the mortality year were mainly because patients 
had more hospital stays in their last year of life compared with those in the years preceding the 
mortality year. This finding was consistent with the observations of previous studies, which 
confirmed that patients with more hospital stays had significantly greater chance of mortality33. 
Indeed, our study showed that hospitalization accounted for most of the annual medical costs 
of patients over the years. A previous study also found that inpatient admissions contributed 
the largest part of the total medical costs for cancer patients, while costs for other services, 
such as chemotherapy and radiotherapy, accounted for no more than 10% of the total direct 
medical costs16. However, hospitalization costs were only from 38% to 64% of the total costs 
of oncology patients in Ontario16, but accounted for up to 96% of the total costs for cancer 
patients in our study. One possible explanation of this discrepancy is that patients who were 
enrolled in this study were approximately 10 years older than those included in the Ontario 
study16. Since the length of stay in hospitals generally increased with ages34, higher percentage 
of medical costs were attributed to hospitalization. 
 
The direct medical costs and survival rates varied across tumour sites. For example, patients 
with cancers of the lip, oral cavity and pharynx and those with lymphatic and hematopoietic 
cancers had relatively larger costs compared with patients with other types of cancers. 
Compared with patients with survivable cancers, those with riskier cancers tended to have a 
shorter life expectancy. In our analyses, a great percentage (24.19%) of patients with 
genitourinary cancer survived beyond 3 years after cancer diagnosis, while a large portion 
(34.11%) of patients with cancer in other and unspecified tumour sites died within 1 year. 
These results had a message for policy makers to implement early health interventions, such as 
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cancer screening tests, in T2DM patients to prevent cancers; and to provide patients who are 
at high risks of lower survivable and/or costly cancers with special care. Apart from sites of 
tumours, patient age is another important factor that affects the life expectancy after cancer 
diagnosis. Life expectancy in younger cancer patients is expected to be longer than that of older 
patients with same conditions35. Indeed, patients in Category 4, with a mean age of 74.6 years, 
were significantly younger than patients in Categories 1 to 3 (Supplemental Table 3). In 
addition, a greater percentage of patients in Category 1 had multiple chronic diseases which 
could contribute to their shorter life expectancy. 
 
Apart from cancers, the presence of comorbidities was another important factor associated with 
increased healthcare expenditure. This study suggested that patients who had a higher CCI, 
diabetic complications and used insulin tended to incur higher costs than patients with lower 
CCI, had no or fewer diabetic complications and used oral antidiabetic drugs. This finding was 
consistent with previous studies that focused on the effects of comorbidities on medical costs 
in oncology patients31,36,37. For example, a costing analysis calculating the costs of elderly 
patients with neuroendocrine tumours found that a comorbidity score of 3 or above 
incrementally increased the monthly medical costs by $1359 for patients who survived beyond 
1 year and $4185 for patients who died within 1 year31. Also, comorbidity was found to be with 
higher medical costs for patients with colon, breast and prostate cancers36. 
 
Our study showed the importance of involving cancer as one of the health states in diabetes 
economic models. The current guidelines for computer simulation modelling of diabetes and 
its complications provide general requirements on model construction, such as considering 
long-term horizons, including multiple complications and carefully selecting a perspective; but 
they do not specifically require the inclusion of cancer19. However, the reliability and validity 
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of diabetes models are considered questionable if cancers are not incorporated as one of the 
modelled complications. It is not only because cancers deteriorate the quality of life and largely 
increase the medical costs of T2DM patients, but also because diabetes is associated with 
increased risks of different cancer types by 10% to 131%9,10. The findings of this study 
therefore provided suggestions for health economists in refining the current diabetes economic 
models and can be used for future cost-effectiveness analyses of health interventions for T2DM.   
 
However, several limitations should be acknowledged. First of all, cancer patients and non-
cancer patients were not matched separately by categories, leading to imbalanced baseline 
characteristics of two groups in a same category. Also, cancer patients in Category 1 had fewer 
matched patients, while those in Category 4 had more matched cases. Secondly, the cost of 
healthcare services incurred in the private sector and the indirect costs due to loss of 
productivity were not taken in consideration. Besides, the packaged charges of HA outpatient 
and inpatient services include pathology investigations, medication within the scale provided 
at the hospitals or clinics and other necessary examinations, but do not cover the costs of 
immunology therapies and surgical operations. Therefore, the results of this study may be 
underestimated. Thirdly, this study assumed that patients enrolled from 2006 to 2017 incurred 
the same unit cost for each healthcare service, without making an adjustment for inflation over 
time.  
 
To conclude, T2DM patients with cancers had higher direct medical costs than those who were 
cancer-free in the year of cancer diagnosis, the years that followed and year of death. 
Hospitalization accounted for the majority of these direct medical costs.  
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Table 1 Baseline characteristics of patients in the cancer group and matched control group 
 Before matching After 1-to-5 propensity score matching 
Characteristics 
Cancer patients 
(n = 21327) 
Cancer patients 
(n = 16869) 
Matched control 
patients 
(n =83046) 
P-value SMD† 
Demographic      
Female, n (%) 10130 (47.5) 8249 (48.9) 41523 (50.0) 0.013* 0.021 
Mean age (SD), year 76.70 (10.72) 76.83 (10.33) 76.81 (6.98) 0.714 0.003 
      
Clinical parameters      
Mean HbA1c (SD), % 7.11 (1.35) 7.08 (1.29) 7.08 (1.24) 0.719 0.003 
Mean fasting glucose (SD), mmol/L 7.38 (2.44) 7.33 (2.34) 7.32 (2.37) 0.645 0.004 
Mean oral glucose tolerance test (OGTT) (SD), mmol/L 9.53 (4.36) 9.57 (4.46) 9.68 (5.20) 0.191 0.022 
Mean SBP (SD), mmHg 133.61 (18.49) 133.78 (18.43) 134.26 (16.98) 0.002* 0.027 
Mean DBP (SD), mmHg 71.79 (10.78) 71.63 (10.69) 71.57 (10.14) 0.460 0.006 
Mean total cholesterol (SD), mmol/L 4.26 (1.02) 4.26 (0.98) 4.27 (0.91) 0.100 0.014 
Mean HDL-C (SD), mmol/L 1.17 (0.34) 1.19 (0.34) 1.20 (0.32) 0.003* 0.026 
Mean TC/HDL-C ratio (SD) 3.89 (1.63) 3.81 (1.37) 3.76 (1.18) <0.001* 0.038 
Mean LDL-C (SD), mmol/L 2.42 (0.86) 2.41 (0.85) 2.41 (0.77) 0.988 0.000 
Mean triglyceride (SD), mmol/L 1.47 (0.88) 1.46 (0.84) 1.46 (0.82) 0.570 0.005 
Mean serum creatinine (SD), umol/l 104.02 (90.47) 102.45 (89.32) 102.61 (73.62) 0.808 0.002 
Mean eGFR (SD), ml/min/1.73m2 72.79 (28.50) 73.03 (27.96) 68.60 (53.39) <0.001* 0.104 
      
Comorbidities      
Mean duration of T2DM (SD), year 4.79 (3.22) 5.09 (3.15) 5.07 (2.96) 0.401 0.007 
    Insulin used, n (%) 4180 (19.6) 3988 (18.7) 15197 (18.3) 0.201 0.011 
    Oral anti-diabetic drugs ever used, n (%) 13009 (61.0) 10594 (62.8) 51405 (61.9) 0.028* 0.019 
History of hypertension, n (%) 17552 (82.3) 14187 (84.1) 69426 (83.6) 0.084 0.000 
    Anti-hypertensive drugs ever used, n (%) 16870 (79.1) 13647 (80.9) 65606 (79.0) <0.001* 0.046 
History of hyperlipidemia, n (%) 9832 (46.1) 8097 (48.0) 39613 (47.7) 0.542 0.005 
    Lipid lowering agents ever used, n (%) 10919 (51.2) 9042 (53.6) 43433 (52.3) 0.003* 0.025 
History of mental health problems, n (%) 512 (2.4) 405 (2.4) 2076 (2.5) 0.247 0.010 
History of obstructive sleep apnea, n (%) 1088 (5.1) 860 (5.1) 4235 (5.1) 0.776 0.002 
History of gallbladder disease, n (%) 981 (4.6) 759 (4.5) 3820 (4.6) 0.713 0.003 
History of musculoskeletal and chronic orthopedic disorders, n (%) 4820 (22.6) 3964 (23.5) 19931 (24.0) 0.191 0.011 
Charlson Comorbidity Index, n (%)    <0.001* 0.098 
    ≤ 3 130 (0.61) 118 (0.7) 914 (1.1)   
    4-6 18687 (87.62) 16565 (98.2) 81800 (98.5)   
    ≥ 7 2508 (11.76) 186 (1.1) 332 (0.4)   
Notes: 
Abbreviations: SMD = Standardized Mean Difference; SD = Standard Deviation; SBP = Systolic Blood Pressure; DBP = Diastolic Blood Pressure; HDL-C = High-density Lipoprotein 
Cholesterol; TC = Total Cholesterol; LDL-C = Low-density Lipoprotein Cholesterol; eGFR = estimated glomerular filtration rate; DM = Diabetes Mellitus 
*Significant difference (p-value <0.05) detected by independence t tests or by chi square tests.  
!SMD <0.200 indicates the balance of baseline covariates. 
Table 2. Mean number of healthcare utilization (visits and length of stays) with standard deviation of cancer and control patients 
 Patients Year N GOPC SOPC A&E Allied health 
Hospitalization utilization† 
General Ward ICU, CCU and HDU 
Cancer patients         
Category 1 Index year 4,811 0.75 (0.04) 5.28 (0.17) 2.53 (0.06) 0.22 (0.03) 38.08 (0.98) 0.45 (0.08) 
Category 2 
Index year 1,377 2.72 (0.15) 15.76 (0.45) 2.96 (0.17) 0.76 (0.13) 34.79 (2.15) 0.38 (0.08) 
Mortality year 1,377 0.85 (0.09) 5.32 (0.29) 2.35 (0.12) 0.22 (0.06) 30.11 (1.66) 0.27 (0.13) 
Category 3 
Index year 725 3.01 (0.22) 14.79 (0.60) 1.64 (0.14) 0.58 (0.12) 22.22 (2.21) 0.47 (0.15) 
Mortality year 725 2.14 (0.18) 11.55 (0.54) 3.58 (0.20) 0.39 (0.13) 41.43 (2.73) 0.28 (0.15) 
Category 4 
Index year 9,956 3.43 (0.06) 11.46 (0.15) 1.07 (0.03) 1.12 (0.07) 12.83 (0.41) 0.24 (0.03) 
Subsequent years 8,256 3.56 (0.07) 7.77 (0.12) 0.95 (0.04) 0.82 (0.07) 4.33 (0.03) 0.04 (0.01) 
Mortality year 1,138 2.15 (0.16) 10.01 (0.41) 3.71 (0.17) 0.51 (0.11) 42.71 (2.51) 0.82 (0.41) 
Control patients         
Category 1 Index year 2,795 0.89 (0.08) 2.05 (0.11) 2.33 (0.08) 0.13 (0.03) 26.50 (1.31) 0.97 (0.17) 
Category 2 
Index year 2,752 2.30 (0.11) 4.56 (0.16) 2.15 (0.10) 0.35 (0.07) 20.68 (1.33) 0.26 (0.07) 
Mortality year 2,752 0.93 (0.08) 1.95 (0.10) 2.28 (0.08) 0.14 (0.03) 27.23 (1.32) 0.93 (0.16) 
Category 3 
Index year 2,575 2.51 (0.11) 4.43 (0.16) 1.56 (0.10) 0.39 (0.08) 11.70 (0.97) 0.12 (0.04) 
Mortality year 2,575 1.80 (0.10) 4.32 (0.16) 3.56 (0.12) 0.29 (0.05) 39.07 (1.72) 0.90 (0.19) 
Category 4 
Index year 74,924 3.65 (0.02) 3.02 (0.02) 0.69 (0.01) 0.46 (0.02) 3.16 (0.09) 0.05 (0.01) 
Subsequent years 64,504 3.36 (0.02) 3.41 (0.03) 0.90 (0.01) 0.48 (0.02) 4.78 (0.09) 0.05 (0.00) 
Mortality year 8,990 1.63 (0.05) 3.83 (0.08) 3.53 (0.06) 0.29 (0.03) 38.46 (0.91) 0.60 (0.08) 
Notes:  
GOPC = General Outpatient Clinic; SOPC = Specialist Outpatient Clinic; A&E = Accident & Emergency; ICU = Intensive Care Unit; CCU = Coronary Care Unit; HDU = 
High Dependency Unit 
Category 1: patients die in the index year; Category 2: patients die in the second year after the index date; Category 3: patients die in the third year after the index date; 
Category 4: patients survive over 3 years after the index date. 
†Mean length of stay  
 
  
Table 3 Mean direct medical cost (US$) with standard deviation of cancer patients in the diagnosis year, in the subsequent years and in the 
mortality year by sites of tumor 
 
  
 Category 1 (N=4811) Category 2 (N=1377) Category 3 (N=725) Category 4 (N=9956) 
Sites of tumor N (%) 
Diagnosis 
year, US$ 
N (%) 
Diagnosis 
year, US$ 
Mortality 
year 
N (%) 
Diagnosis 
year, US$ 
Mortality 
year, US$ 
N (%) 
Diagnosis 
year, US$ 
Subsequent 
year, US$ 
Mortality 
year, US$ 
Lip, oral cavity and 
pharynx 
(N=561) 
97 
(2.02) 
42066.32 
(8380.46) 
46 
(3.34) 
32085.96 
(9166.37) 
28072.39 
(8233.23) 
31 
(4.28) 
28572.1 
(12689.65) 
32069.94 
(12713.72) 
387 
(3.89) 
18429.11 
(2839.51) 
4287.77 
(927.01) 
31820.49 
(12615.83) 
Digestive organs including 
Esophageal, stomach, 
pancreatic, liver, 
gallbladder, colorectal, anal 
cancer  
(N=5843) 
1839 
(38.22) 
28721.00 
(1199.82) 
557 
(40.45) 
29580.42 
(2385.92) 
21468.45 
(1831.32) 
274 
(37.79) 
21570.43 
(2682.81) 
29772.51 
(3089.45) 
3173 
(31.87) 
15199.79 
(576.63) 
5116.07 
(394.76) 
31528.71 
(3072.53) 
Respiratory system 
(N=1645) 
690 
(14.34) 
24539.40 
(1523.83) 
196 
(14.23) 
20745.52 
(2903.76) 
22755.97 
(3166.10) 
92 
(12.69) 
14907.88 
(6090.02) 
27270.16 
(5013.89) 
667 
(6.70) 
10403.65 
(939.00) 
4929.98 
(907.96) 
24753.09 
(4050.22) 
Bone, skin, soft tissue and 
breast 
(N=2539) 
98 
(2.04) 
30130.23 
(5256.34) 
106 
(7.70) 
19988.01 
(4598.54) 
18484.26 
(3587.70) 
74 
(10.21) 
11253.2 
(2757.01) 
28080.38 
(5366.14) 
2261 
(22.71) 
7133.32 
(472.55) 
3694.90 
(349.36) 
30714.18 
(4559.82) 
Genitourinary organs 
including kidney, bladder, 
ureter, uterus, genitalia, 
prostate, and ovary 
(N=3071) 
336 
(6.98) 
32520.42 
(3049.85) 
187 
(13.58) 
26570.94 
(4161.12) 
26221.86 
(4265.75) 
140 
(19.31) 
15634.7 
(2854.77) 
33654.11 
(4513.94) 
2408 
(24.19) 
8207.70 
(467.62) 
4407.84 
(352.36) 
38124.71 
(4988.48) 
Lymphatic and 
hematopoietic tissue 
(N=424) 
110 
(2.29) 
41647.28 
(6277.62) 
40 
(2.90) 
33762.93 
(8612.39) 
18893.08 
(9202.82) 
18  
(2.48) 
28706.56 
(12983.92) 
39598.94 
(12817.13) 
256 
(2.57) 
16653.34 
(2526.06) 
5681.45 
(1279.90) 
36635.21 
(8207.30) 
Other and unspecified sites 
(N=2786) 
1641 
(34.11) 
24478.15 
(1023.28) 
245 
(17.79) 
27372.49 
(3798.34) 
19087.67 
(2097.52) 
96 
(13.24) 
19249.16 
(4525.76) 
30220.68 
(4566.09) 
804  
(8.08) 
12538.97 
(1133.88) 
5045.94 
(851.01) 
31544.20 
(6160.39) 
Notes: Category 1: patients die in the index year; Category 2: patients die in the second year after the index date; Category 3: patients die in the third year after 
the index date; Category 4: patients survive over 3 years after the index date. 
Table 4 Effects of cancer and other baseline covariates on costs in the index year, subsequent years and year of death (generalized linear model 
with log link of Gamma distribution) 
A. Category 1 and 2 
 Category 1 Category 2 
 Index year Index year Mortality year 
Covariates Multiplier 95% CI p-value Multiplier NA <0.001* Multiplier 95% CI p-value 
Constant NA NA <0.001* NA (1.934, 2.359) <0.001* NA NA <0.001* 
Cancer (vs. non-cancer) 1.470 (1.386, 1.559) <0.001* 2.136 (0.866, 1.068) 0.461 1.151 (1.064, 1.245) <0.001* 
Age (vs ≤75) 0.868 (0.822, 0.916) <0.001* 0.961 (0.906, 1.099) 0.963 0.910 (0.839, 0.988) 0.025* 
Male (vs. female) 0.980 (0.934, 1.028) 0.412 0.998 (0.957, 1.156) 0.292 1.027 (0.953, 1.107) 0.487 
Duration of T2DM (vs. ≤5 years) 1.006 (0.958, 1.056) 0.822 1.052 (0.398, 1.438) 0.394 0.955 (0.887, 1.028) 0.218 
CCI (vs. CCI ≤3)          
    4-6 1.638 (0.970, 2.765) 0.065 0.757 (0.772, 3.056) 0.222 1.959 (1.298, 2.957) 0.001* 
    ≥7 1.820 (1.062, 3.120) 0.029* 1.536 (1.136, 1.394) <0.001* 1.824 (1.130, 2.945) 0.014* 
Presence of cardiovascular disease 0.999 (0.949, 1.052) 0.973 1.258 (0.824, 1.390) 0.612 1.054 (0.976, 1.138) 0.182 
Presence of mental health problems 0.990 (0.858, 1.141) 0.885 1.070 (0.905, 1.100) 0.962 0.986 (0.792, 1.227) 0.899 
Presence of hyperlipidemia 1.015 (0.966, 1.066) 0.560 0.998 (0.959, 1.394) 0.127 0.978 (0.907, 1.054) 0.558 
Presence of OSA 1.043 (0.936, 1.162) 0.449 1.156 (0.923, 1.279) 0.319 1.014 (0.875, 1.176) 0.850 
Presence of gallbladder disease 1.100 (1.001, 1.208) 0.046* 1.086 (1.054, 1.293) 0.003* 0.982 (0.853, 1.131) 0.801 
Presence of musculoskeletal and 
chronic orthopedic disorders 
1.031 (0.976, 1.088) 0.279 1.167 (1.133, 1.428) <0.001* 0.998 (0.919, 1.084) 0.958 
Presence of ESRD 1.127 (1.049, 1.211) 0.001* 1.272 (0.895, 1.159) 0.776 1.196 (1.087, 1.317) <0.001* 
Presence of hypertension 1.154 (1.075, 1.239) <0.001* 1.019 (0.959, 1.196) 0.222 1.157 (1.045, 1.280) 0.005* 
Use of insulin 1.072 (1.014, 1.133) 0.014* 1.071 (0.649, 0.803) <0.001* 1.111 (1.021, 1.209) 0.014* 
Use of oral anti-diabetic drugs 0.806 (0.768, 0.846) <0.001* 0.722 (0.771, 0.935) 0.001* 0.797 (0.736, 0.864) <0.001* 
Use of anti-hypertensive drugs 0.821 (0.779, 0.865) <0.001* 0.849 (0.826, 1.020) 0.113 0.775 (0.718, 0.836) <0.001* 
Use of lipid-lowering agents 0.849 (0.807, 0.894) <0.001* 0.918 NA <0.001* 0.856 (0.790, 0.927) <0.001* 
Notes: CI = confidence interval; CCI = Charlson Comorbidity Index; ESRD = End-Stage Renal Disease; OSA = Obstructive Sleep Apnea; T2DM = Type 2 Diabetes 
Mellitus; NA = Not Applicable. 
Category 1: Base cost of index year = US!Base cost of the index year = US$14,366.22; Category 2: Base cost of index year = US$18,306.62; Base cost of mortality year = 
US$12,148.92 
B. Category 3 
 Index year Mortality year 
Covariates Multiplier 95% CI p-value Multiplier 95% CI p-value 
Constant NA NA <0.001* NA NA 0.019* 
Cancer (vs. non-cancer) 2.478 (2.168, 2.831) <0.001* 1.162 (1.069, 1.263) <0.001* 
Age (vs ≤75) 0.899 (0.788, 1.026) 0.115 1.012 (0.928, 1.104) 0.783 
Male (vs. female) 0.939 (0.825, 1.069) 0.343 0.996 (0.923, 1.074) 0.912 
Duration of T2DM (vs. ≤5 years) 0.961 (0.844, 1.094) 0.546 0.975 (0.904, 1.052) 0.512 
CCI (vs. CCI ≤3)       
    4-6 2.522 (0.641, 9.921) 0.186 2.146 (0.877, 5.255) 0.095 
    ≥7 8.075 (1.861, 35.035) 0.005* 2.961 (1.127, 7.778) 0.028* 
Presence of cardiovascular disease 1.365 (1.196, 1.558) <0.001* 1.099 (1.015, 1.19) 0.020* 
Presence of mental health problems 0.839 (0.600, 1.172) 0.303 1.002 (0.842, 1.194) 0.980 
Presence of hyperlipidemia 1.007 (0.881, 1.150) 0.920 0.965 (0.894, 1.043) 0.372 
Presence of OSA 1.235 (0.996, 1.53) 0.054 1.052 (0.912, 1.214) 0.487 
Presence of gallbladder disease 1.294 (1.033, 1.621) 0.025* 0.985 (0.839, 1.155) 0.850 
Presence of musculoskeletal and chronic orthopedic disorders 1.204 (1.042, 1.392) 0.012* 1.114 (1.018, 1.219) 0.019* 
Presence of ESRD 1.338 (1.157, 1.547) <0.001* 1.250 (1.142, 1.368) <0.001* 
Presence of hypertension 0.981 (0.842, 1.143) 0.807 0.983 (0.892, 1.083) 0.724 
Use of insulin 1.092 (0.945, 1.261) 0.231 1.065 (0.977, 1.162) 0.152 
Use of oral anti-diabetic drugs 0.812 (0.705, 0.935) 0.004* 0.793 (0.726, 0.865) <0.001* 
Use of anti-hypertensive drugs 0.878 (0.771, 1.001) 0.052 0.841 (0.777, 0.909) <0.001* 
Use of lipid-lowering agents 0.890 (0.780, 1.016) 0.085 0.896 (0.824, 0.973) 0.009* 
Notes: CI = confidence interval; CCI = Charlson Comorbidity Index; ESRD = End-Stage Renal Disease; OSA = Obstructive Sleep Apnea; T2DM = Type 2 Diabetes 
Mellitus; NA = Not Applicable; Base cost of index year = US$3,446.30; Base cost of mortality year = US$14,987.65 
 
 
C. Category 4 
 Index year Subsequent year Mortality year 
Covariates Multiplier 95% CI p-value Multiplier 95% CI p-value Multiplier 95% CI p-value 
Constant NA NA <0.001* NA NA <0.001* NA NA <0.001* 
Cancer (vs. non-cancer) 5.042 (4.857, 5.234) <0.001* 1.352 (1.295, 1.412) <0.001* 1.213 (1.136, 1.295) <0.001* 
Age (vs ≤75) 1.267 (1.218, 1.318) <0.001* 1.383 (1.343, 1.424) <0.001* 0.909 (0.862, 0.959) <0.001* 
Male (vs. female) 0.999 (0.961, 1.038) 0.961 0.990 (0.963, 1.019) 0.494 1.107 (1.059, 1.157) <0.001* 
Duration of T2DM (vs. ≤5 years) 1.129 (1.086, 1.174) <0.001* 1.062 (1.032, 1.094) <0.001* 0.949 (0.899, 1.001) 0.055 
CCI (vs. CCI ≤3)          
    4-6 1.414 (1.218, 1.642) <0.001* 1.287 (1.036, 1.600) 0.023* 0.960 (0.544, 1.693) 0.887 
    ≥7 4.784 (3.788, 6.042) <0.001* 1.331 (0.995, 1.781) 0.054 0.865 (0.457, 1.637) 0.655 
Presence of cardiovascular disease 1.762 (1.693, 1.833) <0.001* 1.527 (1.481, 1.575) <0.001* 1.083 (1.035, 1.134) 0.001* 
Presence of mental health problems 1.499 (1.359, 1.654) <0.001* 1.351 (1.222, 1.494) <0.001* 0.892 (0.773, 1.029) 0.118 
Presence of hyperlipidemia 0.916 (0.879, 0.956) <0.001* 0.881 (0.855, 0.907) <0.001* 0.929 (0.885, 0.974) 0.003* 
Presence of OSA 1.183 (1.099, 1.272) <0.001* 1.128 (1.058, 1.203) <0.001* 0.993 (0.894, 1.103) 0.893 
Presence of gallbladder disease 1.333 (1.236, 1.438) <0.001* 1.131 (1.064, 1.203) <0.001* 0.986 (0.895, 1.086) 0.769 
Presence of musculoskeletal and 
chronic orthopedic disorders 
1.335 (1.280, 1.392) <0.001* 1.209 (1.170, 1.249) <0.001* 1.053 (0.996, 1.114) 0.070 
Presence of ESRD 2.023 (1.875, 2.184) <0.001* 1.723 (1.603, 1.852) <0.001* 1.136 (1.056, 1.221) 0.001* 
Presence of hypertension 1.063 (1.007, 1.122) 0.026* 1.080 (1.040, 1.121) <0.001* 0.939 (0.888, 0.993) 0.028* 
Use of insulin 1.503 (1.428, 1.582) <0.001* 1.607 (1.553, 1.663) <0.001* 1.127 (1.076, 1.181) <0.001* 
Use of oral anti-diabetic drugs 0.669 (0.640, 0.698) <0.001* 0.581 (0.563, 0.599) <0.001* 0.753 (0.717, 0.791) <0.001* 
Use of anti-hypertensive drugs 0.770 (0.725, 0.817) <0.001* 0.695 (0.668, 0.722) <0.001* 0.874 (0.835, 0.915) <0.001* 
Use of lipid-lowering agents 0.860 (0.823, 0.898) <0.001* 0.825 (0.801, 0.851) <0.001* 0.893 (0.850, 0.938) <0.001* 
Notes: CI = confidence interval; CCI = Charlson Comorbidity Index; ESRD = End-Stage Renal Disease; OSA = Obstructive Sleep Apnea; T2DM = Type 2 Diabetes 
Mellitus; NA = Not Applicable; Base cost of index year = US$1,818.00; Base cost of subsequent year = US$3,612.85; Base cost of mortality year = US$36,805.40 
!
Figure 1 Mean direct medical cost (US$) of patients and proportion of costs attributed by hospitalisation in the cancer and control groups in the index year, 
subsequent years and mortality year 
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Footnotes: Category 1: patients die in the index year; Category 2: patients die in the second year after the index date; Category 3: patients die in the third year after the index date; Category 4: 
patients survive over 3 years after the index date. 
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Supplemental Table 1 ICPC-2 and ICD-9-CM diagnosis codes 
 
Diseases ICPC-2 Code ICD-9-CM Code 
Diabetes mellitus T89, T90, W85 250.x 
Type 1 diabetes mellitus T89 
250.01, 250.03, 250.11, 250.13, 250.21, 
250.23, 250.31, 250.33, 250.41, 250.43, 
250.51, 250.53, 250.61, 250.63, 250.71, 
250.73, 250.81, 250.83, 250.91, 250.93 
Type 2 diabetes mellitus T90 
250.00, 250.02, 250.10, 250.12, 250.20, 
250.22, 250.30, 250.32, 250.40, 250.42, 
250.50, 250.52, 250.60, 250.62, 250.70, 
250.72, 250.80, 250.82, 250.90, 250.92 
Hypertension K86, K87 401.x 
Hyperlipidaemia T93 272.0-272.4 
Mental health P74-P77 296-311 
Obstructive sleep apnoea P06 
327.20, 327.23, 780.51, 780.53, 780.57, 
786.09 
Gallbladder disease U13 574-575.9 
Musculoskeletal and chronic 
orthopaedic disorders 
L72-L81, L88-L90, L95-L96 710-739.99 
Malignant neoplasm 
A79, B72, B73, B74, D74, 
D75, D76, D77, F74, H75, 
K72, N74, L71, R84, R85, S77, 
T71, T73, X76, U75, U76, U77, 
W72,  X75, X77, Y78,  
140.0-208.92 
Malignant neoplasm of lip, oral 
cavity, and pharynx 
 140.0-148.9 
Malignant neoplasm of 
digestive organs and 
peritoneum 
D74, D75, D76, D77 150.0-158.9 
Malignant neoplasm of 
respiratory and intrathoracic 
organs 
K72, R84, R85 160.0-165.9 
Malignant neoplasm of bone, 
connective tissue, skin, and 
breast 
L71, S77, X76 170.0-176.9 
Malignant neoplasm of 
genitourinary organs 
U75, U76, U77, X75, X77, Y78 179-187.9 
Malignant neoplasm of other 
and unspecified sites 
A79, F74, H75, N74, T71, T73, 
W72 
190.0-198.89 
Malignant neoplasm of 
lymphatic and hematopoietic 
tissue 
B72, B73, B74 200.00-208.92 
  
Supplemental Table 2 Unit cost of healthcare services  
Healthcare services†! Cost (HK$) Cost (US$)‡ 
Clinic visit   
    General outpatient clinic  445 per visit 57 per visit 
    Specialist outpatient clinic  1,190 per visit 153 per visit 
Accident and emergency  1,230 per visit 158 per visit 
Allied health professionals   
    Clinical Psychologist 550 per visit 71 per visit 
    Dietitian 550 per visit 71 per visit 
    Occupational Therapist 550 per visit 71 per visit 
    Physiotherapist 550 per visit 71 per visit 
    Smoking counselling and cessation centre 550 per visit 71 per visit 
Hospitalisation   
    General ward  5,100 per day 654 per day 
    Intensive care unit 24,400 per day 3,128 per day 
    Cardiac care unit 24,400 per day 3,128 per day 
    High dependency unit 13,650 per day 1,750 per day 
Note:  
† Data source: 2017 Hong Kong SAR Government Gazette and Hospital Authority Ordinance 
(chapter 113): Public charges – non-eligible persons.  
‡!Converted at a fixed exchange rate of 1 US= 7.80HK. 
Supplemental Table 3 Baseline characteristics of type 2 diabetes mellitus patients in 4 Categories 
(A) Cancer group 
Characteristics 
Category 1 
(n=4811) 
Category 2 
(n=1377) 
Category 3 
(n=725) 
Category 4 
(n=9956) 
p-value 
Demographic      
Female, n (%) 2122 (44.1) 611 (44.4) 356 (49.1) 5167 (51.9) <0.001* 
Mean age (SD), year 80.72 (9.86)† 78.73 (9.90) 78.35 (9.58) 74.58 (10.03) <0.001* 
      
Clinical parameters      
Mean HbA1c (SD), % 7.04 (1.38)† 7.10 (1.28) 7.11 (1.27) 7.09 (1.24) 0.081 
Mean fasting glucose (SD), mmol/L 7.31 (2.57)† 7.35 (2.50) 7.31 (2.50) 7.34 (2.18) 0.897 
Mean oral glucose tolerance test (OGTT) (SD), mmol/L 9.50 (4.67) 9.37 (3.94) 9.12 (3.27) 9.68 (4.48) 0.197 
Mean systolic blood pressure (SD), mmHg 133.25 (20.07) 133.86 (18.99) 133.70 (18.40) 134.03 (17.51) 0.136 
Mean diastolic blood pressure (SD), mmHg 70.27 (11.21)† 70.55 (10.79) 70.75 (10.55) 72.50 (10.34) <0.001* 
Mean total cholesterol (SD), mmol/L 4.18 !1.06) 4.24 (1.00) 4.31 (1.07) 4.29 (0.93) <0.001* 
Mean HDL-C (SD), mmol/L 1.16 (0.35)† 1.17 (0.34) 1.20 (0.36) 1.21 (0.33) <0.001* 
Mean TC/HDL-C ratio (SD) 3.89 (1.59)† 3.84 (1.30) 3.82 (1.29) 3.77 (1.26) <0.001* 
Mean LDL-C (SD), mmol/L 2.40 (0.93) 2.42 (0.86) 2.46 (0.90) 2.41 (0.80) 0.36 
Mean triglyceride, mmol/L 1.37 (0.70)† 1.40 (0.82) 1.43 (0.81) 1.51 (0.91) <0.001* 
Mean serum creatinine (SD), umol/L 117.91 (115.71)† 110.97 (103.62) 113.74 (03.64) 92.91 (67.33) <0.001* 
Mean eGFR (SD), ml/min/1.73m2 69.58 (32.32)† 70.18 (29.18) 68.50 (27.86) 75.44 (25.10) <0.001* 
      
Comorbidities      
Mean duration of T2DM (SD), year 5.48 (3.13)† 5.01 (2.99) 4.45 (2.62) 4.96 (3.20) <0.001* 
        Insulin ever used, n (%) 991 (20.6) 263 (19.1) 163 (22.5) 1742 (17.5) <0.001* 
        Oral anti-diabetic drugs ever used, n (%) 2271 (47.2) 620 (45.0) 307 (42.3) 7397 (74.3) <0.001* 
History of hypertension, n (%) 4176 (86.8) 1158 (84.1) 591 (81.5) 8263 (83.0) <0.001* 
        Anti-hypertensive drugs ever used, n (%) 3584 (74.5) 985 (71.5) 537 (74.1) 8532 (85.7) <0.001* 
History of hyperlipidaemia, n (%) 2242 (46.6) 598 (43.4) 282 (38.9) 4968 (49.9) <0.001* 
        Lipid lowering agents ever used, n (%) 1746 (36.3) 461 (33.5) 245 (33.8) 6581 (66.1) <0.001* 
History of mental health problems, n (%) 96 (2.0) 30 (2.2) 22 (3.0) 259 (2.6) 0.085 
History of obstructive sleep apnoea, n (%) 241 (5.0) 70 (5.1) 34 (4.7) 518 (5.2) 0.882 
History of gallbladder disease, n (%) 308 (6.4) 78 (5.7) 31 (4.3) 348 (3.5) <0.001* 
History of musculoskeletal and chronic orthopaedic disorders, n (%) 1289 (26.8) 353 (25.6) 126 (17.4) 2200 (22.1) <0.001* 
Charlson Comorbidity Index, n (%)     <0.001* 
        ≤ 3 10 (0.2) 4 (0.3) 0 (0.0) 110 (1.1)  
        4-6 4710 (97.9) 1354 (98.3) 721 (99.5) 9777 (98.2)  
        ≥ 7  96 (2.0) 19 (1.4) 4 (0.6) 70 (0.7)  
Notes: SD = Standard Deviation; HDL-C = High-density Lipoprotein Cholesterol; TC = Total Cholesterol; LDL-C = Low-density Lipoprotein Cholesterol; eGFR = estimated glomerular 
filtration rate; T2DM = Type 2 Diabetes Mellitus 
*Significant difference (p-value <0.05) detected by analysis of variance tests or by chi square tests. 
† Significant difference (p-value<0.05) between cancer group and non-cancer group within the same category, detected by t-test or by chi square tests. 
 
 
 
(B) Non-cancer group 
Characteristics 
Category 1 
(n=5516) 
Category 2 
(n=6199) 
Category 3 
(n=6141) 
Category 4 
(n=77984) 
p-value 
Demographic      
Female, n (%) 2153 (39.0) 2371 (38.3) 2343 (38.2) 39336 (50.4) <0.001* 
Mean age (SD), year 79.13 (6.68) 79.33 (6.37) 79.62 (6.22) 76.66 (6.95) <0.001* 
      
Clinical parameters      
Mean HbA1c (SD), % 7.21 (1.58) 7.25 (1.56) 7.33 (1.63) 7.06 (1.22) <0.001* 
Mean fasting glucose (SD), mmol/L 7.61 (3.22) 7.58 (3.18) 7.64 (3.11) 7.30 (2.30) <0.001* 
Mean oral glucose tolerance test (OGTT) (SD), mmol/L 9.19 (6.72) 9.24 (3.63) 9.57 (9.14) 9.69 (4.75) 0.005* 
Mean systolic blood pressure (SD), mmHg 133.76 (19.75) 133.55 (19.34) 132.90 (18.90) 134.15 (16.79) 0.007* 
Mean diastolic blood pressure (SD), mmHg 70.84 (11.22) 71.04 (10.93) 70.85 (10.86) 71.62 (10.06) <0.001* 
Mean total cholesterol (SD), mmol/L 4.15 (1.03) 4.21 (1.02) 4.21 (0.99) 4.27 (0.90) <0.001* 
Mean HDL-C (SD), mmol/L 1.11 (1.11) 1.12 (0.31) 1.12 (0.32) 1.20 (0.32) <0.001* 
Mean TC/HDL-C ratio (SD) 3.98 (1.40) 4.00 (1.50) 3.98 (1.42) 3.75 (1.14) <0.001* 
Mean LDL-C (SD), mmol/L 2.40 (0.86) 2.45 (0.86) 2.43 (0.84) 2.41 (0.77) <0.001* 
Mean triglyceride, mmol/L 1.44 (0.90) 1.45 (0.85) 1.45 (0.81) 1.46 (0.81) <0.001* 
Mean serum creatinine (SD), umol/L 54.21 (143.83) 46.97 (108.71) 46.07 (105.44) 15.93 (55.03) <0.001* 
Mean eGFR (SD), ml/min/1.73m2 157.75 (165.53) 139.41 (125.81) 132.89 (107.99) 98.07 (58.08) <0.001* 
      
Comorbidities      
Mean duration of T2DM (SD), year 4.99 (2.84) 4.86 (2.74) 4.65 (2.61) 2.61 (0.08) <0.001* 
        Insulin ever used, n (%) 1726 (31.3) 1962 (31.7) 1894 (30.8) 13799 (17.7) <0.001* 
        Oral anti-diabetic drugs ever used, n (%) 1480 (26.8) 1585 (25.6) 1542 925.1) 49735 (63.8) <0.001* 
History of hypertension, n (%) 4673 (84.7) 5183 (83.6) 4974 (81.0) 65121 (83.5) <0.001* 
        Anti-hypertensive drugs ever used, n (%) 2953 (53.5) 3297 (53.2) 3294 (53.6) 62198 (79.8) <0.001* 
History of hyperlipidaemia, n (%) 2216 (41.5) 2571 (41.5) 2455 (40.0) 37597 (48.2) <0.001* 
        Lipid lowering agents ever used, n (%) 1251 (22.7) 1300 (21.0) 1348 (22.0) 41748 (53.5) <0.001* 
History of mental health problems, n (%) 177 (3.2) 150 (2.4) 158 (2.6) 1963 (2.5) 0.018* 
History of obstructive sleep apnoea, n (%) 378 (6.9) 397 (6.4) 398 (6.5) 3980 (5.1) <0.001* 
History of gallbladder disease, n (%) 334 (6.1) 431 (7.0) 404 (6.6) 3549 (4.6) <0.001* 
History of musculoskeletal and chronic orthopaedic disorders, n (%) 1379 (25.0) 1450 (23.39) 1419 (23.11) 18602 (23.9) <0.001* 
Charlson Comorbidity Index, n (%)     <0.001* 
        ≤ 3 6 (0.1) 4 (0.1) 3 (0.1) 920 (1.2)  
        4-6 5398 (97.9) 6137 (99.0) 6090 (99.2) 76870 (98.6)  
        ≥ 7  112 (2.0) 58 (0.9) 48 (0.8) 194 (0.3)  
Notes: SD = Standard Deviation; HDL-C = High-density Lipoprotein Cholesterol; TC = Total Cholesterol; LDL-C = Low-density Lipoprotein Cholesterol; eGFR = estimated glomerular 
filtration rate; T2DM = Type 2 Diabetes Mellitus 
*Significant difference (p-value <0.05) detected by analysis of variance tests or by chi square tests. 
 
Supplemental Figure 1 Flowchart of the study
!
Cohort Entry Year Cancer patients Control patients 
2006-2009 1,820 8,780 
2010-2012 4,251 20,991 
2013-2015 6,305 31,149 
2016-2017 4,493 22,126 
!
Cancer group Control group 
288,685 patients in records 
287,484 patients with T2DM were identified 
by ICD-9-CM/ICPC diagnosis codes 
103 patients were excluded due to 
first records in the year of 2018  
26,843 patients with diagnosis of 
cancer were identified by relevant 
ICD-9-CM / ICPC diagnosis codes 
4,959 patients were 
excluded due to the onset 
of cancer prior to the 
diagnosis of T2DM  
557 patients were 
excluded due to the onset 
of cancer prior to 2007 
21,327 eligible patients with 
diagnosis of cancer 
260,435 eligible patients without 
diagnosis of cancer 
1-to-5 propensity score matching 
16,869 eligible cancer patients 83,046 eligible control cases 
287,381 eligible patients with T2DM 
1201 patients without T2DM were 
excluded  
Supplemental Figure 2 Pyramid of propensity score distribution among T2DM patients with and 
without cancers.  
 
!
Supplemental Figure 3 Mean direct medical costs incurred in the index year and in the mortality 
year among type 2 diabetes mellitus patients with and without cancers 
 
 
p-values between Categories Category 2 Category 3 Category 4 
Cancer    
      Category 1 <0.001* 0.002* <0.001* 
      Category 2 -- <0.001* <0.001* 
      Category 3 -- -- 0.394 
Control    
      Category 1 <0.001* 0.010* <0.001* 
      Category 2 -- <0.001* <0.001* 
      Category 3 -- -- <0.001* 
!
